Clinical Trial

Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II trial studies how well pembrolizumab works in treating participants with ovarian cancer that has come back after previous treatment. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread.
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2018-11-05; most recent amendment 2024-12-06.
Status change: Active, Not Recruiting → Unknown 2024-12-06
Status change: Recruiting → Active, Not Recruiting 2024-04-11
Status change: Not Yet Recruiting → Recruiting 2019-06-26
Trial Details
NCT Number NCT03732950
Lead Sponsor Jonsson Comprehensive Cancer Center
Collaborators: Merck Sharp & Dohme LLC
Conditions Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Enrollment 5 participants
Start Date 2019-03-06
Primary Completion 2023-12-05 (estimated)
Study Completion 2025-03-06 (estimated)
Updated on ClinicalTrials.gov 2024-04-15